ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None202020192018 Date Title 01 April 2020 FDA Accepts BLA for RYONCIL and Agrees to Priority Review 30 March 2020 Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting 20 March 2020 Change of Director's Interest Notice 17 March 2020 Appendix 2A 10 March 2020 Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease 27 February 2020 Mesoblast Provides Half Year Results and Corporate Update 27 February 2020 Half Year Financial Results Presentation 27 February 2020 Half Year Report and Accounts (including Appendix 4D) 25 February 2020 Mesoblast Half Year FY 2020 Financial Results Analyst Call 24 February 2020 Ryoncil Results in Children with Acute GvHD Presented at TCT 21 February 2020 Appendix 3G 20 February 2020 Positive Outcomes Using Remestemcel-L in Chronic GVHD 07 February 2020 Appendix 2A 03 February 2020 Mesoblast Submits Completed BLA for Ryoncil to US FDA 29 January 2020 Appendix 4C - quarterly 24 January 2020 Appendix 2A 15 January 2020 Biotech Showcase Presentation 15 January 2020 MSB Presents Commercial Plans at 2020 Biotech Showcase 02 January 2020 Appendix 2A 02 January 2020 MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
